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Abstract
Background: Identifying and treating persons with human immunodeficiency virus (HIV) infection early in their disease
stage is considered an effective means of reducing the impact of the disease. We compared the cost-effectiveness of HIV
screening in three settings, sexually transmitted disease (STD) clinics serving men who have sex with men, hospital
emergency departments (EDs), settings where patients are likely to be diagnosed early, and inpatient diagnosis based on
clinical manifestations.
Methods and Findings: We developed the Progression and Transmission of HIV/AIDS model, a health state transition model
that tracks index patients and their infected partners from HIV infection to death. We used program characteristics for each
setting to compare the incremental cost per quality-adjusted life year gained from early versus late diagnosis and treatment.
We ran the model for 10,000 index patients for each setting, examining alternative scenarios, excluding and including
transmission to partners, and assuming HAART was initiated at a CD4 count of either 350 or 500 cells/mL. Screening in STD
clinics and EDs was cost-effective compared with diagnosing inpatients, even when including only the benefits to the index
patients. Screening patients in STD clinics, who have less-advanced disease, was cost-effective compared with ED screening
when treatment with HAART was initiated at a CD4 count of 500 cells/mL. When the benefits of reduced transmission to
partners from early diagnosis were included, screening in settings with less-advanced disease stages was cost-saving
compared with screening later in the course of infection. The study was limited by a small number of observations on CD4
count at diagnosis and by including transmission only to first generation partners of the index patients.
Conclusions: HIV prevention efforts can be advanced by screening in settings where patients present with less-advanced
stages of HIV infection and by initiating treatment with HAART earlier in the course of infection.
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Introduction
More than 1.1 million people in the U.S. are living with human
immunodeficiency virus (HIV) infection, of whom approximately
one fifth are undiagnosed and unaware of their infection.[1]
Identifying persons unaware of their infections as early as possible
is a national public health priority.[2] Transmission rates for
persons unaware of their HIV infection are estimated to be more
than three times the rates for persons aware of their infection.[3]
There are also substantial benefits for the health of HIV-infected
persons and reduced transmission of HIV to uninfected persons
associated with the early initiation of highly active antiretroviral
therapy (HAART) for those aware of their serostatus.[4–6]
The Centers for Disease Control and Prevention (CDC) and
other public health agencies have promoted HIV testing in
sexually transmitted disease (STD) clinics in the U.S. for almost
two decades. To increase early diagnosis, the CDC now
recommends that ‘‘diagnostic HIV testing and opt-out HIV
screening be a part of routine clinical care in all health-care
settings,’’ such as hospital emergency departments (EDs) and
outpatient clinics.[7] HIV diagnostic testing of hospitalized
persons with opportunistic infections or other findings suggestive
of HIV has been widely available since the mid-1980s.
Previous cost-effectiveness analyses of HIV testing have shown
that population-based screening protocols are cost-effective except
when there is very low HIV prevalence.[8] [9,10] These results
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focused on screening at various intervals and that incorporated
national data on HIV prevalence and incidence combined with
plausible assumptions about background testing and detection of
HIV through case finding. However, there is a paucity of research
comparing the costs and effectiveness of diagnosing HIV infection
in specific settings where persons vary in the stage of their disease
at the time of testing.[11]
Recent literature indicates that early initiation of HAART may
be both effective and cost-effective in preventing and treating
HIV.[4–6,12–16] In December, 2009 the Department of Health
and Human Services Panel on Antiretroviral Guidelines recom-
mended antiretroviral therapy for patients with CD4 counts up to
500 cells/mL, and half the panel recommended starting therapy at
higher CD4 counts.[6] These recommendations were based on a
reduction in AIDS-related mortality from earlier initiation of
HAART found in observational research studies. Clinical studies
have shown that viral load suppression through antiretroviral
therapy may also delay or prevent some non-AIDS-defining
complications including kidney, liver, and cardiovascular dis-
ease.[6] HIV modeling studies have suggested that universal
voluntary HIV testing and immediate implementation of HAART
(‘‘test and treat’’ strategies) could have a major impact on the HIV
epidemic through a reduction in viral load and decreased
transmission.[17,18]
In this study, we evaluate the cost-effectiveness of HIV testing
based on the CD4 cell count at diagnosis. To do this, we use
illustrative examples comparing routine screening in STD clinics
in urban areas with a large population of men who have sex with
men (MSM); routine screening in hospital EDs; and diagnostic
testing based on clinical manifestations of HIV infection in
inpatient units. Routine screening is a process where age-eligible
persons are offered point-of-care rapid HIV testing in accordance
with CDC’s revised recommendations for HIV testing in health
care settings.[7] Two of the settings, STD clinics and EDs, were
emphasized in these recommendations.[7] HIV testing is common
in STD clinics, and some EDs have begun pilot programs for HIV
screening.[19–21] Most of the literature on screening in EDs has
focused on the feasibility and acceptability of these procedures.
Including the effects of both disease progression and transmission,
we compare the cost-effectiveness of testing in these settings to
each other and to diagnostic, inpatient testing. We examine both
the case of initiating treatment of HIV-infected patients with
HAART at a CD4 count of 350 cells/mL and 500 cells/mL. The
analysis accounts for program costs, treatment-related costs, and
health outcomes of both the individuals diagnosed with HIV in
these settings and the partners they infect with HIV.
Methods
Model
We developed the Progression and Transmission of HIV/AIDS
(PATH) model to estimate the quality-adjusted life expectancy and
costs of persons diagnosed with HIV infection at various stages of
the disease. PATH is an individual Monte Carlo simulation health
state transition model that tracks index patients through different
phases of HIV from infection until death. It also includes
transmission and follows the infected partners of the index patients
until death. The model was developed in Microsoft Excel (Version
2003, Microsoft Corporation, Redmond, WA) with Visual Basic
Applications (Version 6.3, Microsoft Corporation, Redmond,
WA). Distributions, random numbers, and simulations were
generated with @Risk (Version 4.5.7, industrial edition, Palisade
Corporation, Ithaca, NY). The unit of time progression is a three-
month period representing a quarter of a calendar year, with costs,
quality-adjusted life years (QALYs) lost, and other outcomes
computed for each quarter. A summary of key input parameters
for the model is presented in Table 1. The assumptions, technical
details of the model, schematic flowcharts, and the full set of input
parameters are presented in Appendix S1, The Progression and
Transmission of HIV/AIDS (PATH) Model.
We created three scenarios — one each for routine screening in
STD clinics, routine screening in hospital EDs, and diagnoses
made in inpatient settings. We ran the PATH model for 10,000
iterations for each scenario. Each iteration represented an
individual, or an index person, whom we tracked from infection
until death. The three scenarios differed only in CD4 cell count at
diagnosis, undiagnosed seropositivity rate, associated screening
costs, and assumptions made about the proportion of newly
diagnosed persons who were linked to care.
Test settings and patient populations
For STD clinics, we assumed that persons visit a clinic for sexual
education, health examinations, tests, and treatments, and that
screening with a rapid HIV test is routinely conducted as a part of
a program for STD prevention. We based our analysis on clinics
located in an urban area with a large MSM population in which
many persons are tested frequently. For diagnosis in an ED, we
assumed that people visit an ED facility because they need urgent
or emergency medical care and are routinely screened with a rapid
test. For HIV diagnosis in inpatient facilities, we assumed that
physicians conduct diagnostic testing (e.g., order HIV tests based
on the clinical manifestations of patients) using conventional
testing with an HIV enzyme immunoassay (EIA) of serum
obtained by venipuncture. In all three settings, positive EIA and
rapid tests were assumed to be confirmed with a Western blot.
For CD4 cell count at diagnosis in STD clinics, we used data
from the One-on-One program of the Public Health – Seattle &
King County (PHSKC) STD Clinic in Washington state from
January 2006 to June 2008 (Table 2).(Written communication, M
Golden, Public Health-Seattle & King County STD clinic and the
Center for AIDS & STD, University of Washington, Seattle, May,
2009. See also [22]) The One-on-One program refers people
diagnosed with HIV at Seattle and King County public health
clinics to treatment. This clinic is representative of a testing
program in an urban area with a large MSM population where the
clients are tested with increasing frequency.[23] For the MSM
tested, the median CD4 cell count at diagnosis was 429 cells/mL
(range 5–1,287 cells/mL).
For CD4 cell count at diagnosis in EDs, we used the results from
a program of expanded HIV screening and on-site rapid testing
primarily among adult Hispanic and non-Hispanic black patients
in an urban academic ED in Oakland, CA (Table 2) (median CD4
count 356 cells/mL; range 4–1,020 cells/mL).[19]
For CD4 cell count at diagnosis in inpatient facilities, we used
data on inpatients discharged with a new diagnosis of HIV or
AIDS at two academic medical centers in Boston, MA (Table 2)
(median CD4 cell count at diagnosis 36 cells/mL; range 2–
847 cells/mL).[24] These data are consistent with other studies.
(Written communication, D. Rimland, VA Medical Center,
Decatur, GA, August, 2009. See also [25])
Linkage to care
We assumed that all patients diagnosed in the inpatient setting
were linked to care in the quarter following diagnosis. For patients
diagnosed in the ED and STD settings, we assumed that 65% were
linked to care in the quarter following diagnosis, and that an
additional 15% were linked to care by the time their CD4 cell
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assumed to be diagnosed as inpatients and were linked to care
when their CD4 cell count decreased to 36 cells/mL, the median
CD4 cell count at diagnosis in inpatient facilities.[24] These
assumptions are consistent with data from studies of linkage to care
in various settings.[26–29]
Disease progression
We included the following phases of HIV infection as health
states in the PATH model: acute infection, asymptomatic HIV
infection, symptomatic HIV infection or acquired immunodeficien-
cy syndrome (AIDS), and death. CD4 cell count and HIV viral load
were the key determinants of disease progression in this model.
When individuals were linked to care according to the above
assumptions, they became eligible for HAART when their CD4 cell
count decreased to a threshold of either 350 or 500 cells/mLt o
model previous and current treatment guidelines.[6], [30] Persons
linked to care with higher CD4 cell counts did not initiate HAART
until their CD4 cell count decreased to these thresholds, whereas
persons linked to care with CD4 cell counts under the thresholds
initiated HAART in the quarter following diagnosis. The PATH
model included up to four suppressive HAART regimens followed
by a single salvage non-suppressive regimen.
Life expectancy and QALYs lost to infection
We predicted the probability of death during each quarter
following diagnosis based on probabilities related to age and CD4
count at initiation of antiretroviral treatment.[31,32] We assigned
a utility weight ranging from 0 (for death) to 1 (for perfect health)
to an individual’s health state for each quarter survived, based on
that individual’s CD4 cell count during that quarter and whether
the individual had an opportunistic illness (OI) such as Pneumocystis
jiroveci pneumonia (PCP). We used quality-of-life weights from
Tengs and Lin[33] and aggregated them over the person’s life. We
then subtracted this sum from the QALYs associated with an HIV-
uninfected person, assuming a QALY of 1 (good health) for the
entire life expectancy from the age of HIV infection,[34] to
estimate the QALYs lost due to HIV infection. Measuring QALYs
lost due to infection resulted in consistent quality of life estimates
when transmissions to partners were included in the model. A
decrease in QALYs lost in one setting compared with QALYs lost
in another represents a gain in QALYs in the first setting.
Costs
We included both treatment costs and program costs in 2009 dollars
estimated from the provider perspective. Treatment costs, derived
from lifetime cost estimates by Schackmanet al.,[35] included the costs
Table 1. Summary of Input Parameters.
Variable Base Case Value Range Source
Natural Disease Progression
CD4 cell count when infected (cells/mL) 900 750–900 [47]
HIV viral load set point (log10 copies/ml) 4.5 4.0–5.0 [48,49]
Cumulative quarterly probability of developing an opportunistic infection (%) 0.3–35.3
1 [8,50]
HAART Regimens
Minimum CD4 cell count to initiate HAART (cells/mL) 350/500 [6]
Suppressed HIV viral load level (log10 copies/ml) 1.3 1.0–2.7 [51]
Rebound HIV viral load level (log10 copies/ml) 3.7 3.1–4.5 [52]
Maximum number of HAART regimens 4
2
Probability of virologic suppression in HAART regimens 1–4 0.80
2
Quarterly Costs (2009 $) [35]
Inpatient and outpatient resource utilization 905–6,007
3
Additional costs of opportunistic infections (each occurrence) 3,492–20,542
4
Additional cost of HAART (each quarter) 4,143–13,699
5
Annual Rates of Sexual Transmission (# events per year per person) [38,39]
Acute 0.751
Non-acute unaware 0.093
Non-acute aware, not on HAART 0.041
Non-acute aware, on HAART 0.008
Other Variables
Age at infection (years) 35 30–40
6
Discount rate for costs and quality-adjusted life years (QALYs) 3% [37]
Utility weights to estimate quality-adjusted life years (QALYs) .935–.702
7 [33]
1The lower and upper bounds reflect probabilities for CD4 cell counts of .500 cells/mL and 0–50 cells/mL, respectively.
2Expert opinion (2009).
3Costs vary by CD4 cell count, HAART usage, and history of AIDS-defining opportunistic infection.
4These numbers represent costs for different opportunistic illnesses.
5The lower and upper bounds reflect costs for the first and fourth HAART regimens. Costs for the other regimens lie in between these values.
6Written communication, R. Song, Centers for Disease Control and Prevention, June, 2008.
7Utility weights vary by CD4 cell count and presence of opportunistic infection.
doi:10.1371/journal.pone.0019936.t001
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monitoring (i.e., CD4 cell count, HIV viral load determination, and
genotypic antiretroviral resistance testing), diagnosing and treating
OIs, and costs incurred during the last month of life.
To estimate program costs, we calculated only the marginal
costs associated with testing and counseling in a particular setting
for both HIV-infected and uninfected persons. We assumed that
the settings evaluated already had HIV testing ability, so fixed and
start-up costs were not included in our calculations. For inpatient
facilities, we estimated the laboratory costs for conventional HIV
testing and post-test counseling costs only for HIV-infected
persons. For the ED and STD clinic settings, we included
additional costs associated with rapid HIV testing, such as the costs
for collecting specimens, the test kits, and post-test counseling for
infected persons. We did not include the cost of administrative
overhead and other costs that would have been incurred in the
absence of a screening program. These program costs were varied
in the sensitivity analysis, particularly for STD clinics, to reflect the
repeat testing by MSM that often occurs in these settings.[23]
To include the costs of persons who are tested but are not HIV
infected, we computed program costs per HIV-infected person
identified usingthefollowingformula foreachsetting:{[p*Cost HIV+
+ (12p) * Cost HIV2]/p} where Cost HIV+ = cost of testing an HIV-
infected person, Cost HIV2 = cost of testing an uninfected person,
and p = the undiagnosed HIV seropositivity rate in that particular
setting. For example, in inpatient settings the total cost per HIV-
infected person derived from Table 2 data equals [(0.143) *
62.4+(120.143) * 5.3)]/0.143=$94.1.
Cost HIV+ and Cost HIV2 for a particular setting were derived from
estimates by Farnham et al.[36] (Table 2). We discounted future costs
and QALYs at a rate of 3% per year[37] from the quarter of infection.
Disease transmission
We used a quarterly probability of HIV transmission per
infected individual derived from an annual transmission rate to
add HIV transmission from index patients to the model (Table 1).
We estimated transmission probabilities on the basis of a model,
first developed by Pinkerton[38] and later updated by Prabhu
et al.[39], which is explained in Appendix S1. Transmission
probabilities were derived for those acutely infected and unaware
of their infection, those non-acutely infected and unaware, and for
those non-acutely infected who were aware and either not on or on
a HAART regimen. We used separate rates for sexual and
injection drug use (IDU) transmission, and we assumed that 12.9%
of the index persons were IDU in all settings.[40]
We evaluated secondary transmissions for a single generation of
transmissions, i.e., transmission of HIV from index persons to their
partners. We assumed that all partners who acquired infections
from an index patient were diagnosed at a CD4 cell count of
500 cells/mL and were linked to care based on assumptions similar
to those for persons diagnosed in ED and STD clinics. We
standardized the linkage to care and treatment approach for
infected partners because our primary interest is assessing the
timing of diagnosis, linkage to care, and initiation of treatment of
index patients on the cost-effectiveness of HIV diagnosis in
different settings.
Measuring cost-effectiveness
We estimated the costs (treatment and program) and QALYs
lost to infection for each of the 10,000 index patients for each
setting, and we computed the mean costs (C) and mean QALYs
lost to infection (Q) for each setting. We then used the ratio of the
differences in mean costs and differences in mean QALYs to
compute the incremental cost-effectiveness ratio (ICER). To
calculate ICERs with transmission effects, we included the costs
and QALYs lost to infection for the index persons and their
infected partners. We calculated 95 percent confidence intervals
for mean and incremental costs and QALYs.
Incremental cost-effectiveness ratios may be negative, indicating
cost-savings resulting from an increase in QALYs gained and a
Table 2. Input Parameters That Vary With Settings.
Setting
Median CD4 Cell
Count at Diagnosis
(cells/mL)
Undiagnosed
Seropositivity Rate in
the Setting (%)
Cost of a Positive HIV
Test/Negative HIV Test
(2009 $)
1
Total Program
Cost per HIV-
Infected Person
(2009 $) Linkage to Care Assumptions
Inpatient
(diagnostic testing)
36 14.3[53] 62.4/5.3 94.1 100% following diagnosis
Range
2 2–847
Sample size
3 69[24]
Emergency
department
(screening)
356 0.7[19] 73.4/16.5 2,413.50 65% following diagnosis; 15% when
CD4 cell count=200 cells/mL; 20% as
inpatients
Range 4–1,020
Sample size 55[19]
Sexually transmitted
disease clinic
(screening)
429 0.8[54]
4 85.4/19.7 2,527.50 65% following diagnosis; 15% when
CD4 cell count=200 cells/mL; 20% as
inpatients
Range 5–1,287
Sample size 398[54]
4
1Test costs were derived from [36].
2Range of CD4 cell count values in the source study.
3Number of persons diagnosed in the source study.
4Also, written communication with M. Golden, Public Health-Seattle & King County STD Clinic and the Center for AIDS & STD, University of Washington, Seattle, May,
2009.
doi:10.1371/journal.pone.0019936.t002
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required to achieve the gain in QALYs. For the latter, $100,000
per QALY gained represents a reasonable current estimate of the
amount society is willing to pay to gain a QALY, although this
amount may be even higher.[41–43]
Sensitivity analyses
The base case simulation of the model for 10,000 iterations used
point estimates for all variables in the model. A simulation of 10,000
iterations was necessary as the outcomes of the model reflected the
probabilities of the occurrence of different events, such as the
development of an opportunistic illness or the probability of dying
during the quarter after HAART had been initiated, for each of the
10,000 index persons. Values of the model variables were drawn
directly from the literature as noted previously and in Appendix S1.
We present base case results both excluding and including
transmission and with the assumption of patients initiating HAART
at a CD4 count of either 350 or 500 cells/mL.
We then performed one-way sensitivity analyses of the impact of
changesinselectedvariablesontheSTD-EDICERsinthebasecase,
assuming initiation of HAART at a CD4 count of 350 cells/mL.
These variables included the undiagnosed HIV seropositivity rate in
the different testing settings, overall program costs, STD clinic
program costs, HIV treatment costs, age at infection, the probability
of viral load suppression, and the transmission probabilities. The
differences between testing in the STD and ED settings were
analyzed in more detail by varying the CD4 count at diagnosis in the
STD setting. The impact of linkage to care was examined by
assuming that all index patients and their partners were immediately
linked to care.
To reflect the overall uncertainty in decision analytic models,
we also ran a probabilistic sensitivity analysis by assigning
distributions around the point estimates of key variables based
on accepted conventions.[44] These variables included: age at
infection; CD4 count when infected; CD4 count at diagnosis; set
point viral load; the levels of suppressed, rebound, and salvage
therapy viral load; and the decline in CD4 count at a specific viral
load stratum. Normal distributions were used for most variables.
Given the importance of CD4 count at diagnosis for this analysis
and the small sample sizes in the studies reporting these values, we
used the cumulative distribution based on the minimum,
maximum, and inter-quartile values for these variables in an
attempt to most accurately use the available data.
Results
Cost-effectiveness of HIV testing in different settings
Initiate HAART at a CD4 count of 350 cells/mL. In the
base case analysis, assuming initial treatment with HAART at a
CD4 count of 350 cells/mL and excluding the effects of HIV
transmission (Table 3), individuals diagnosed with HIV in the ED
setting gained an additional 2.5 (2.3–2.6) QALYs compared with
individuals diagnosed as inpatients. Mean discounted total costs
(program costs and treatment costs) incurred were $398,833
($395,898–$401,768) for those diagnosed in ED settings and
$313,655 ($310,854–$316,456) for persons diagnosed with HIV in
inpatient settings. Compared to diagnosis in inpatient settings, the
cost per QALY gained for a diagnosis in the ED setting was
$34,597. The mean discounted total cost of diagnosing individuals
in STD clinics was $399,844 ($396,909–$402,779) or $1,012 more
Table 3. Cost-Effectiveness Analysis of Testing in Different Settings, Initiate HAART at CD4 cell count=350 cells/mL.
Setting
Mean Discounted
Costs (2009 $)
Mean Discounted Quality-
Adjusted Life Years
Lost to Infection (QALY) Incremental Cost
Incremental
QALY Gained
Incremental
Cost-Effectiveness
Ratio (ICER) ($/QALY)
Excluding Transmission
Inpatient (diagnostic
testing)
313,655 7.313 – – –
(95% CI)
1 (310,854–316,456) (7.229–7.397) – – –
Emergency department
(screening)
398,833 4.851 85,178 2.462 34,597
(95% CI) (395,898–401,768) (4.767–4.935) (81,121–89,235) (2.343–2.581) –
Sexually transmitted
disease clinic (screening)
399,844 4.851 1,012 0.000 Undefined
2
(95% CI) (396,909–402,779) (4.767–4.935) (23,140–5,162) – –
Including Transmission
Inpatient (diagnostic
testing)
817,419 14.097 – – –
(95% CI) (809,196–825,642) (13.904–14.290) – – –
Emergency department
(screening)
816,824 10.130 2595 3.967 Cost-saving
3
(95% CI) (808,954–824,694) (9.958–10.302) (211,977–10,787) (3.708–4.226) –
Sexually transmitted
disease clinic (screening)
800,716 9.866 216,108 0.264 Cost-saving
3
(95% CI) (792,950–808,482) (9.699–10.033) (227,164–25,052) (0.024–0.504) –
1CI=confidence interval.
2These ratios are undefined because there is no increase in QALYs between the emergency department and sexually transmitted disease clinic settings. The incremental
cost would be divided by zero.
3Screening in the setting is cost-saving compared with screening in the previous setting because there is an increase in QALYs and a decrease in costs.
doi:10.1371/journal.pone.0019936.t003
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HIV infection were the same in both the ED and STD clinic
settings because we assumed that index patients linked to care in
these settings initiated HAART at the same time following
infection, i.e., when their CD4 counts decreased to 350 cells/mL.
Therefore, the ICER between these settings was undefined, given
that the incremental costs were divided by a zero change in
QALYs.
In other model results (data not shown), index patients in both
the ED and STD clinic settings started HAART at a median CD4
count of 345 cells/mL, had a mean time from infection to the start
of HAART of 11.2 years, were on HAART for a mean time of
25.3 years, and experienced the onset of AIDS an average of 22.0
years from the time of infection. Mean life expectancy with
infection was 36.5 years, which is consistent with the litera-
ture.[45]
We estimated that persons diagnosed in STD clinics transmitted
HIV to an average of 1.37 individuals compared with 1.44
individuals for those diagnosed in EDs and 1.83 individuals for
those diagnosed in inpatient settings. When including the costs and
QALYs gained that were associated with transmission, diagnosing
persons in ED settings was found to be cost-saving compared with
diagnosis in inpatient facilities (except at the upper bound of the
95% confidence interval for incremental costs). Diagnosis in STD
clinics was also cost-saving when compared with ED settings and
inpatient facilities (Table 3).
Initiate HAART at a CD4 count of 500 cells/mL. In the
case excluding transmission effects where treatment with HAART
for the index patient was initiated at a CD4 count of 500 cells/mL
(Table 4), the cost per QALY gained for screening in the ED
compared with inpatient testing was essentially the same as in
Table 3. However, when comparing screening in STD clinic
settings with ED screening, there was an increase of 0.4 (0.2–0.5)
QALYs and an ICER of approximately $60,000 per QALY
gained. The median CD4 count at initiation of HAART was
415 cells/mL for index patients screened in STD clinics compared
with 345 cells/mL for those screened in EDs (results not shown).
Index patients in STD clinic settings began HAART an average of
10.4 years following infection compared with 11.2 years among
those screened in the ED, and they were on HAART for an
average of 26.8 years compared with 25.1 years for ED index
patients (data not shown). When the effects of reduced
transmission were included in the analysis, screening in the ED
setting remained cost-saving compared with inpatient testing
(except at the upper bound of the 95% confidence interval) and
screening in STD clinic settings remained cost-saving compared
with ED screening (Table 4).
Sensitivity analyses
The results of the one-way sensitivity analyses in Table 5
comparing screening in STD clinic settings with ED screening
showed that the base case results in Table 3 were robust with
respect to changes in key variables in the analysis. Variations in
undiagnosed HIV seropositivity rates, program costs, HIV
treatment costs, age at infection, the probability of viral load
suppression, and transmission rates had little impact on the STD-
ED incremental cost-effectiveness ratios. These ICERs remained
undefined when the transmission effects were excluded, given the
zero change in QALYs between the two settings. Screening in the
STD clinic setting remained cost-saving compared with ED
screening when the benefits of reduced transmission were
included. When the CD4 count at diagnosis in the STD setting
was varied by increments of 20 cells/mL from 356 cells/mL (equal
to the base case value for the ED setting) to 436 cells/mL, STD
Table 4. Cost-Effectiveness Analysis of Testing in Different Settings, Initiate HAART at CD4 cell count=500 cells/mL.
Setting
Mean Discounted
Costs (2009 $)
Mean Discounted
Quality-Adjusted Life Years
Lost to Infection (QALY)
Incremental
Cost
Incremental
QALY Gained
Incremental
Cost-Effectiveness
Ratio (ICER) ($/QALY)
Excluding Transmission
Inpatient (diagnostic
testing)
313,520 7.331 – – –
(95% CI)
1 (310,726–316,314) (7.247–7.415) – – –
Emergency department
(screening)
396,164 4.942 82,644 2.389 34,594
(95% CI) (393,273–399,055) (4.859–5.025) (78,624–86,664) (2.271–2.507) –
Sexually transmitted
disease clinic (screening)
417,883 4.580 21,719 0.362 59,997
(95% CI) (414,935–420,831) (4.498–4.662) (17,590–25,848) (0.245–0.479) –
Including Transmission
Inpatient (diagnostic
testing)
867,404 13.519 – – –
(95% CI) (858,483–876,325) (13.334–13.704) – – –
Emergency department
(screening)
859,993 9.712 27,411 3.807 Cost-saving
2
(95% CI) (851,501–868,485) (9.549–9.875) (219,728–4,906 (3.560–4.054) –
Sexually transmitted
disease clinic (screening)
856,432 8.986 23,561 0.726 Cost-saving
2
(95% CI) (848,077–864,787) (8.828–9.144) (215,474–8,352) (0.499–0.953) –
1CI=confidence interval.
2Screening in the setting is cost-saving compared with screening in the previous setting because there is an increase in QALYs and a decrease in costs.
doi:10.1371/journal.pone.0019936.t004
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for a difference as small as 20 cells/mL when transmission benefits
were included in the analysis. Assuming 100 percent linkage to
care for both index patients and partners also did not change the
results of the analysis.
In sensitivity analysis (data not shown), the ED-inpatient ICERs
were all in the same range as for the base case. Thus, the results for
all the incremental cost-effectiveness ratios were robust in the
sensitivity analysis.
When the model was run with a probabilistic sensitivity analysis
around key variables (Table 6), excluding transmission effects and
assuming treatment with HAART at a CD4 count of 350 cells/mL,
the ED-inpatient incremental cost-effectiveness ratio was approx-
imately the same as in the base case (Table 3). However, the STD-
ED ICER was $44,000/QALY gained compared with the
undefined STD-ED ICER in the base case (Table 3). When
transmission benefits were included in the analysis, initiating
treatment with HAART at a CD4 count of either 350 or
Table 5. Sensitivity Analysis, Base Case Model, Screening in Sexually Transmitted Disease (STD) Clinic Settings Versus Emergency
Department (ED) Screening.
Variable Values Incremental Cost-Effectiveness Ratio (ICER)
Excluding Transmission
1 Including Transmission
2
Undiagnosed HIV Seropositivity
Base Case STD: 0.8%; ED: 0.7% Undefined Cost-saving
Low STD: 0.56%; ED: 0.5% Undefined Cost-saving
High STD: 3.0%; ED: 1.5% Undefined Cost-saving
Program Cost Adjustment Factor
Base Case 1.0 Undefined Cost-saving
Low 0.5 Undefined Cost-saving
High 2.0 Undefined Cost-saving
Program Cost: STD Clinic Only Adjustment Factor
Base Case 1.0 Undefined Cost-saving
Low 0.5 Undefined Cost-saving
High 2.0 Undefined Cost-saving
Treatment Cost Adjustment Factor
Base Case 1.0 Undefined Cost-saving
Low 0.8 Undefined Cost-saving
High 1.2 Undefined Cost-saving
Age
Base Case 35 Undefined Cost-saving
Low 30 Undefined Cost-saving
High 40 Undefined Cost-saving
Probability of Viral Load Suppression
Base Case 0.80 Undefined Cost-saving
Low 0.72 Undefined Cost-saving
High 0.88 Undefined Cost-saving
Annual Rates of Transmission
Base Case Undefined Cost-saving
Reduce by 25% Undefined Cost-saving
Reduce by 50% Undefined Cost-saving
STD Clinic CD4 Cell Count at Diagnosis (cells/mL)
356 (same as ED) Undefined Undefined
376 Undefined Cost-saving
396 Undefined Cost-saving
416 Undefined Cost-saving
436 Undefined Cost-saving
Linkage to Care
Base Case (65%, 15%, 20%) Undefined Cost-saving
100% Undefined Cost-saving
1These ratios are undefined because there is no increase in QALYs between the ED and STD clinic settings. The incremental cost would be divided by zero.
2Screening in the STD clinic setting is cost-saving compared with screening in the ED setting because there is an increase in QALYs and a decrease in costs.
doi:10.1371/journal.pone.0019936.t005
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inpatient and STD-ED comparisons (except at the upper bound of
the 95% confidence interval).
Discussion
Although individuals should always be tested when they present
with clinical manifestations in inpatient settings, HIV prevention
efforts can be improved by screening in settings where people
present with less-advanced stages of HIV infection and by
initiating treatment with HAART at those earlier disease stages.
Our results illustrate the cost-effectiveness of testing for HIV
infection in settings where diagnosis at higher CD4 counts early in
the course of disease is likely to occur and when treatment with
HAART is initiated earlier in the course of infection.
If HAART is initiated at a CD4 count of 350 cells/mL, early
diagnosis is cost-effective for index patients when comparing either
the ED or STD clinic setting with inpatient diagnosis. Although
the mean discounted program and treatment costs were higher in
the ED and STD clinic settings compared with inpatient diagnosis
because patients were on HAART regimens for longer periods,
there were reduced QALYs lost to HIV infection due to the
delayed onset of AIDS that resulted in incremental cost-
effectiveness ratios of less than $100,000 per QALY gained.[41–
43] When the effects of transmission were included in the analysis,
screening in the ED and STD clinic settings was cost-saving
compared with inpatient testing.
In the base case analysis excluding transmission effects,
diagnosis of index patients in STD clinics compared with the
ED setting involved slightly higher costs because the earlier
average diagnosis in STD clinics at a median CD4 count of
429 cells/mL (compared with 356 cells/mL in the ED setting)
resulted in monitoring costs for an additional duration for the
index patients. However, index patients in both settings were
assumed to initiate a HAART regimen only when their CD4
counts decreased to 350 cells/mL. This fact accounted for the lack
of differences in the disease progression variables, e.g., mean time
from infection to start of HAART and mean time on HAART, for
index patients in the STD clinic and ED settings and for the
identical QALYs lost to infection in both settings.
However, earlier diagnosis in the STD clinic setting compared
with the ED setting implies that index patients spend less time
unaware of their serostatus in the non-acute phase of HIV infection,
resulting in fewer transmissions per person. The costs of treating
HIV infection comprise approximately 99% of the total costs
associated with each setting. Even a small change in the number of
transmissions per index patient (1.37 in STD clinics compared with
1.44 in EDs and 1.83 in the inpatient setting) results in significant
treatment costs averted and makes screening in the ED setting cost-
saving compared with inpatient diagnosis and screening in STD
clinics cost-saving compared with the ED setting.
Thus, the cost-effectiveness issues change fundamentally when
the benefits of reduced transmission are included in the model.
Earlier diagnosis averts more secondary infections from the index
patients. This outcome results from the modeled reduction in risky
behavior following diagnosis and reduced transmission due to HIV
viral load suppression achieved with HAART. These transmission
effects resulted in a reduced number of secondary infections and
reduced total costs (i.e., the combined costs of HIV infection for
the index patient and their infected partners). Thus, settings where
individuals were diagnosed earlier in their infections were cost-
saving compared to settings with later diagnosis when transmission
effects were included. These transmission benefits occurred even
when there were very small differences in CD4 counts between
index patients in the ED and STD clinic settings, given the
treatment costs saved.
Table 6. Cost-Effectiveness Analysis of Testing in Different Settings, Probabilistic Sensitivity Analysis, Initiate HAART at CD4 cell
count=350 cells/mL.
Setting
Mean Discounted
Costs (2009 $)
Mean Discounted
Quality-Adjusted Life Years
Lost to Infection (QALY)
Incremental
Cost
Incremental
QALY Gained
Incremental
Cost-Effectiveness
Ratio (ICER) ($/QALY)
Excluding Transmission
Inpatient (diagnostic testing) 334,003 7.573 – – –
(95% CI)
1 (330,517–337,489) (7.468–7.678) – – –
Emergency department
(screening)
401,807 5.506 67,804 2.067 32,803
(95% CI) (398,584–405,030) (5.413–5.599) (63,056–72,552) (1.927–2.207) –
Sexually transmitted disease
clinic (screening)
409,952 5.320 8,145 0.186 43,790
(95% CI) (406,744–413,160) (5.228–5.412) (3,598–12,692) (0.056–0.316) –
Including Transmission
Inpatient (diagnostic testing) 794,190 13.491 – – –
(95% CI) (785,663–802,717) (13.296–13.686) – – –
Emergency department
(screening)
793,861 10.330 2329 3.161 Cost-saving
2
(95% CI) (785,864–801,858) (10.157–10.503) (212,019–11,361) (2.900–3.422) –
Sexually transmitted disease
clinic (screening)
783,900 9.896 29,961 0.434 Cost-saving
2
(95% CI) (776,056–791,744) (9.727–10.065) (221,163–1,241) (0.192–0.676) –
1CI=confidence interval.
2Screening in the setting is cost-saving compared with screening in the previous setting because there is an increase in QALYs and a decrease in costs.
doi:10.1371/journal.pone.0019936.t006
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HAART began at a CD4 count of 500 cells/mL. Screening index
patients in STD clinic settings was now cost-effective compared
with ED settings because treatment for more patients began
immediately when they were diagnosed with HIV, reducing the
quality-adjusted life expectancy lost to HIV infection. Early
treatment with HAART suppresses viral load, increases the
patient’s CD4 count and the maximum CD4 count attainable,
and lowers the rate of CD4 count decline. All of these factors lower
the probability of death for patients on HAART compared with
HAART-naı ¨ve patients.
In our base case analysis, in which we assumed that all
individuals in each setting were tested at the median CD4 count
for that setting, 429 cells/mL for STD clinics, 356 cells/mL for
EDs, and 36 cells/mL for inpatient settings, there were no changes
in QALYs between the ED and STD clinic settings (Table 3),
given that index patients in both the ED and STD clinics initiated
HAART at the same time following infection, i.e., when their CD4
counts decreased to 350 cells/mL. When we drew values from
cumulative distributions around the median CD4 counts at
diagnosis in the different settings in the probabilistic sensitivity
analysis, screening of index patients in STD clinics became cost-
effective compared with ED diagnosis (an ICER of $44,000 per
QALY in Table 6). Due to the nature of these distributions,
individuals were tested in both settings at CD4 counts higher and
lower than the median. For example, model results (not presented)
showed that 25% of individuals in the ED setting were diagnosed
at CD4 counts of 185 cells/mL or less compared with 309 cells/mL
for STD clinics. Thus, individuals in the ED would, on average,
have had a much more advanced disease stage at diagnosis
compared with those diagnosed in the STD clinic setting, although
both would be referred to treatment immediately after diagnosis.
Therefore, if individuals in the STD clinic and ED settings are
actually tested at CD4 counts that vary widely from the median,
there can be a benefit to the index patients of testing and initiating
HAART, on average, earlier in STD clinics than in emergency
departments.
Limitations of the Analysis
Our work is subject to a number of limitations. Data regarding
disease status (CD4 cell count and HIV viral load at diagnosis) for
the different HIV testing settings are very limited. In particular,
the data we used for CD4 cell count at diagnosis were drawn from
observations at a small number of locations. We, therefore, may
not be able to generalize our findings to all EDs, STD clinics, and
inpatient settings. Our analysis indicates that more data,
particularly on CD4 count at diagnosis by setting, would be
useful, given the differences between our base case results and
those in the probabilistic sensitivity analysis where we allowed the
CD4 count at diagnosis to vary around the median in each setting.
On the other hand, our main finding, that diagnosing persons
living with HIV at higher CD4 counts is cost-effective, is robust
even with the limited data.
We may have under-estimated the costs for screening in STD
clinics because we did not include any fixed costs and because
many STD settings include clinics that strongly encourage repeat
testing among their MSM clients. However, it would be
inconsistent to use average costs (that include fixed costs) for
STD clinics and marginal or incremental costs (that exclude fixed
costs) for the ED and inpatient settings. Although repeat testing
would increase STD clinic costs, we showed in the one-way
sensitivity analysis that increasing STD screening costs by 100
percent did not change the results of the analysis. In a separate
simulation (results not shown), we increased STD screening costs
Table 7. Cost-Effectiveness Analysis of Testing in Different Settings, Probabilistic Sensitivity Analysis, Initiate HAART at CD4 cell
count=500 cells/mL.
Setting
Mean Discounted
Costs (2009 $)
Mean Discounted
Quality-Adjusted Life Years
Lost to Infection (QALY)
Incremental
Cost
Incremental
QALY Gained
Incremental
Cost-Effectiveness
Ratio (ICER) ($/QALY)
Excluding Transmission
Inpatient (diagnostic testing) 339,830 7.498 – – –
(95% CI)
1 (336,301–343,359) (7.393–7.603) – – –
Emergency department
(screening)
415,374 5.356 75,544 2.142 35,268
(95% CI) (412,053–418,695) (5.263–5.449) (70,698–80,390) (2.002–2.282) –
Sexually transmitted disease
clinic (screening)
427,799 5.119 12,425 0.237 52,427
(95% CI) (424,494–431,104) (5.028–5.210) (7,740–17,110) (0.107–0.367) –
Including Transmission
Inpatient (diagnostic testing) 854,757 12.990 – – –
(95% CI) (845,609–863,905) (12.800–13.180) – – –
Emergency department
(screening)
853,593 9.808 21,164 3.182 Cost-saving
2
(95% CI) (844,936–862,250) (9.641–9.975) (213,759–11,431) (2.929–3.435) –
Sexually transmitted disease
clinic (screening)
839,551 9.285 214,042 0.523 Cost-saving
2
(95% CI) (830,981–848,121) (9.125–9.445) (226,223–21,861) (0.292–0.754) –
1CI=confidence interval.
2Screening in the setting is cost-saving compared with screening in the previous setting because there is an increase in QALYs and a decrease in costs.
doi:10.1371/journal.pone.0019936.t007
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change the overall cost-effectiveness results of the analysis.
Data on linkage to care are sparse and may vary by subgroups
in the population. The assumptions in this model are consistent
with the existing literature, and our sensitivity analysis did not
show any impact of changes in these assumptions. However, better
data, particularly on linkage to care in different settings, will
improve future modeling efforts.
The PATH model does not incorporate any measure of ongoing
transmission beyond the first generation partners. Thus, we may
underestimate the cost-effectiveness of early diagnosis as some
additional secondary transmission might also be averted. On the
other hand, some infections we consider to be averted might only
be delayed. Use of a dynamic transmission model in an economic
analysis could improve the estimates of the cost-effectiveness of
different HIV screening programs, but would introduce additional
complexity and uncertainty related to sexual mixing patterns,
which are not well defined. Our estimates of the number of
transmissions per index partner are consistent with those in the
literature.[10,46] Decreasing the transmission probabilities in the
sensitivity analysis reduced the number of transmissions per index
partner but did not affect the overall cost-effectiveness results.
Conclusions
Our analysis with the PATH model showed that identifying
persons with HIV while their CD4 counts are high is cost-effective
and potentially cost-saving, when the effects of early diagnosis on
transmission are considered. Although inpatient testing based on
clinical manifestations of disease should always be undertaken, our
results should prompt additional HIV case-finding efforts,
particularly in venues such as STD clinics and emergency
departments, where persons are likely to have higher CD4 counts
at the time of diagnosis. The results can help guide decisions about
implementing HIV screening and should be used to encourage the
collection of additional data on CD4 count at diagnosis to identify
more settings where persons are likely to be tested early in the
course of disease. Our model also showed that initiating treatment
with HAART earlier in the course of infection is cost-effective,
making early diagnosis even more beneficial.
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